Lupin has announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States. The product is the generic equivalent of Xarelto for Oral Suspension, 1 mg/mL, marketed by Janssen Pharmaceuticals, Inc.
Rivaroxaban for Oral Suspension, 1 mg/mL is indicated for use in:
Treatment of venous thromboembolism (VTE) and reduction of the risk of recurrent VTE in pediatric patients from birth to less than 18 years of age, following at least five days of initial treatment with a parenteral anticoagulant.
Thromboprophylaxis in pediatric patients aged 2 years and above with congenital heart disease who have undergone the Fontan procedure.
According to IQVIA MAT data, Rivaroxaban for Oral Suspension, 1 mg/mL (RLD Xarelto) had estimated annual sales of USD 11 million in the U.S.